



## **Alternative medicines to enhance the efficacy and safety of Anticancer therapy**

**S.Mariselvi<sup>1</sup>, Alok Tiwari<sup>2</sup>, Sivakumar Ponnusamy<sup>3</sup>, E.N. Gaviraj<sup>4</sup>**

**1.**Assistant Professor, Department of Zoology, NallamuthuGounder Mahalingam College, Pollachi, Tamilnadu, India.

**2.**Assistant Professor, Department of Yogic Science, Dr. RammanoharLohia Avadh University, Ayodhya, U.P., India, 224001.

**3.**Associate Professor, Department of Computer Science and Engineering ,SRM Institute of Science and Technology, Delhi-NCR Campus, Delhi - Meerut Expy, Modinagar, Uttar Pradesh 201204.

**4.**Professor and HOD, Department of Pharmacognosy, BLDEA's SSM College of Pharmacy and Research Centre Vijayapur 586103 Karnataka.

Correspondence Email: [selsiya123@gmail.com](mailto:selsiya123@gmail.com)

### **ABSTRACT**

*Present the findings of a holistic healthcare therapy aimed at decreasing the negative impacts of anticancer therapy & cancer signs while also increasing the quality of life for patients. Meals that induce inflammation were to be avoided in favor of those having anti-oxidant & anti qualities, according to dietary guidelines. The Radiation Therapy Oncology Association scale was used to measure the degree of radiodermatitis. Most of the participants were undergoing or had recently completed traditional cancer treatment. Twenty-one cancer sufferers declined or stopped traditional antitumor therapy despite their oncologist's advice; after the integrated oncology visit, seven out of seventeen patients receiving follow-up elected to embrace conventional oncologic treatment. Clinic could help cancer sufferers live longer by decreasing the adverse reactions of cancer therapeutics & boosting their life quality.*

**Keywords:** anticancer therapy; radiodermatitis; Cancer treatment

Received: 18.02.2022

Revised :12.03.2022

Accepted: 24.03.2022

### **INTRODUCTION**

A new analysis of the 468 patients with different malignancies undertaken in hospitals exposed a 48.9% prevalence of current or past utilize the use of Complementary Medicine (CM) [1]. Surprisingly, the majority of patients were ignorant of the possible interactions & negative effects when they were prescribed CMs. 2 Alternative treatments were commonly used during cancer settings to improve health, enhance the quality of care, & alleviate illness symptoms & negative effects of traditional treatment [2-4]. Participants who were at minimum one obey were re-examined to measure the reaction to integrate therapy. On average, a first obey meaasurement was performed 1-2 years after the start appointment, & then each 1, 2, or three months afterward when, depending on the detailed medical status [5].

As a result, the center uses an inverted grading scale, in which the main degree of proof of two interactions correlates to the major levels of depression advice [6]. The Association of Internal Medicine suggests using this technology to improve the understanding of in vivo and/or in vitro interaction among Computed Tomography(CT)& medicinal herbs for medical use. Good communication skills among medicinal herbs & pharmaceuticals would be included in this category [7]. For example, H. Perforate does have flipped scoring that should not be used during oncologic treatment; this herb was already linked to research lab proof in vitro & in vivo, and also medical news stories of pharmacodynamic intervention with a demonstrated danger of lowering anti-cancer practice model [8]. Curcuma long, on the other hand, has VB grade, which implies it could be used throughout oncologic treatment and therefore has no toxicity, health consequences, or adverse disruptions and it also has a cumulative impact on oxaliplatin & gemcitabine [9-11].

For the anonymized investigation of this study, every patient received a numeric identity number & required to sign a security declaration & informed consent was obtained [12]. Personal details, overall health status, progression of cancer, metastatic spread, translation, category of cancer treatment, & potential explanations for not having undergone a treatment, such as when the physician rejected, and also the intensity of every side effect have all been documented in detail during the first discussion [13].

The impact of the treatments on the primary symptoms was evaluated in participants who can be seen to obey. The main clinical information and also the outcomes acquired were then summarized [14]. That information was then analyzed by a third-party specialist who hasn't been part of a clinical group that managed the people with cancer appointments & medications. Clinical investigations have shown that amifostine protects against nephrotoxicity, esophagi is, neurotoxicity, myelotoxicity, & mucositis induced by chemo and radiotherapy. Furthermore, in contrast, preclinical researches indicate that amifostine might defend from anthracycline-induced cardiotoxicity and also chemotherapeutic & radiation-induced mutagenicity [15] numerous clinical investigations have shown that pretreatment using cisplatin, cyclophosphamide, or a combination of two drugs reduces the incidence of nephrotoxicity, neurotoxicity & myelotoxicity in individuals experiencing amifostine.

There's been no evidence of a decline in the antitumor activity of the chemotherapeutic regiment, and in many other trials, treated patients with amifostine seem to have a large number of respondents. Second dissection has been used to examine tumor response. The second-look technique was available to 86 participants in the amifostine category & 79 participants in the chemotherapeutic category. In the end, 60 individuals in the amifostine category & 52 participants in the chemotherapeutic category were treated, with five patients in each category being deemed ineligible. Nonresponders would be those who could not go through the process.

Although 75 percent of amifostine-treated participants used to react compared to 65 percent of chemotherapy-only participants, the difference has not been statistically meaningful [16]. In any case, the research found no evidence of a reduced reaction in amifostine-treated participants. There has been no difference in the survival exchange rate between the two groups after a mean follow-up of more than 41 months. Research on twenty-five patients with the non-small-cell lung of metastatic disease was undertaken by Schiller et al. Participants was given amifostine + cisplatin on day one, & thereafter vinblastine without amifostine preparation every week [17-19]. First 18 patient's received amifostine of 910 mg/m<sup>2</sup>, while a latter 7 received 740mg/m<sup>2</sup>. Treatment is maintained until the condition worsened, intolerable toxicity developed, or six cycles were already completed. The participants were on average 62 years old. A total of 16 of the 25 patients exhibited a partial reaction. There were no comprehensive answers found.

## MATERIAL AND METHODS

The Homeopathy Medicine handled transaction processing, filtering, coding, & assessment. The analytical software was used to conduct the analysis. The frequency analysis of the sample was determined for every variable in this research. As previously indicated in the Research procedures section, the assessment of the complaints was undertaken by contrasting G levels at the initial consultation with G levels at the follow-up appointment. The Mann Whitney U method is utilized to test a degree for radiodermatitis in 2 independent groups, each with a two-tailed statistical significance.

Breast cancer was perhaps the most common malignancy among the 357 people with cancer, with 204 people, followed by malignancies of the stomach, lungs, & ovary. Hematological malignancies were extremely uncommon. The high number of women with breast cancer was partially attributable to the pathology's prevalent character, and also referrals from Lucca's oncology unit, which would be known for its expertise in breast cancer treatment. The cases of cancer in this research, therefore, were not confined to those in the early stages: 123 individuals have advanced to the point where the disease has spread to the regional lymph nodes or who had distant metastases; 33 individuals used to have a tumor recur, or 9.5 percent of people used to have a family history of breast cancer. Several 184 participants, or 51.5 percent of its total, had at most one follow-up session. The major signs described by individuals at the IO center in Lucca, and also the traditional cancer treatments which might have produced them, can be seen in Table 1. The most common side effects of CT were asthenia & nausea/vomiting. Sadness, stress, & asthenia were the most common cancer-related complaints. Hot flushes & joint pain have been the most common symptoms associated with CT, as expected. Lymphedema would be a condition that affects the lymphatic system.

**Table 1. Main Symptoms Possibly**

<b>Cancer symptoms</b>	
Symptoms	Number of patients
Depression	22
Anxiety	18
Fatigue	15
Pain	5
Insomnia	5
<b>Comorbidities</b>	

Joint pain	11
Depression	9
Gastritis	5
Asthma	5
<b>Effects of RT</b>	
Radiodermatitis	22
Dysgeusia	5

An examination of the treatment outcome was seen in Table 2. Because there was no appropriate control group, the concentration of symptomatology has been especially in comparison before and after the interdisciplinary diagnosis, assessed from G0 to G3, as underlined in the Methodology chapter, & analyzed extremely shortly after the last part of round anti-cancer treatment & besides throughout treatment to refresh the interdisciplinary treatment.

**Table 2. Effectiveness of Complementary Medicine Treatment**

Symptoms	Total no. of Patients	Total no. of Patients G0	Total no. of Patients G1	Total no. of Patients G2	Total no. of Patients G3	P <sup>a</sup>
Hot flashes (first visit)	43	0	9	19	18	<0.02
Hot flashes (follow-up visit)	43	21	13	11	2	
Fatigue (First visit)	35	0	3	16	19	<0.002
Fatigue (follow-up visit)	35	15	14	6	4	
Joint pain (First visit)	23	0	3	15	8	<0.06
Joint pain (follow-up visit)	23	8	6	8	6	
Depression (First visit)	19	0	2	11	8	<0.02
Depression (follow-up visit)	19	11	6	3	0	
Nausea (First visit)	17	0	3	8	8	<0.02
Nausea (follow-up visit)	17	8	7	5	0	

Radiodermatitis as a result of Radiation Therapy(RT) was deserving of its topic. In this instance, an integrated treatment was usually required before the commencement of RT or during its early stages, because radiodermatitis increases as the RT series progress. As a result, the radiodermatitis severity in the group of 30 consecutive patients having RT was measured using an Radiation Therapy Oncology Group (RTOG) scale at the start and end of the treatment.<sup>18</sup> Seventeen patients who underwent integrated RT were examined by conducting thirteen individuals who did not get integrated therapy. In the group receiving integrated therapy, 15 patients have G1, 1 patient has G2, & 1 patient knowledgeable G3 damage, while the team not receiving integrated care, 15 patients had G1, two patients have G2, & four patients used to have G3 toxic effects. Because the outcomes of CM therapy in people with cancer were not compared to the case of a controlling group compared, which was not able to match the outcomes of CM therapy in people with cancer with the outcomes of a comparison group. Randomized prospective & uncontrolled trials, preferably matched placebo, should be done in the future. Additional business would be that the results were calculated using a very broad nonspecific approach of evaluation—one that did not use specialized systems of symptom measurement. To assess radiodermatitis symptoms, 16 more relevant criteria were being used, which have been matched to those of a group compared to the untreated patients who have not been randomized. Oncologists & CM providers may share the same goal of minimizing adverse effects of anticancer medicines. CMs could be utilized to reduce the side effects of cancer therapeutics without increasing the risk of medication toxicity. In reality, in the authors' medical knowledge, no serious adverse effects or drug reactions owing to alternative treatments have already been observed. Medical professionals who seem to be specialists in CMs could help in this situation by investigating if cancer sufferers should use CMs, asking about their views of the potential advantages, & providing information about potential unrecognized conflicts among conventional medicines & CM therapy. All of this information, and also a participant's subjective stress assessment, could be reviewed

by the oncology team at frequent meetings, resulting in a good encounter & laying the groundwork for true accreditation of healthcare.

## RESULTS AND DISCUSSIONS

The Clinic for Counteract The effect & Lifestyle in Oncology at the Lucca hospital collaborates with the clinical oncology department with psycho-oncologists. Several cancer women want guidance on how to minimize the side effects of RT & CM& CT therapies of hot flushes caused by Estrogen Therapy (ET).

Around 6% of participants visit the clinics to deny or halt traditional anticancer therapy, against their oncologist's advice, & requesting an "alternative" other" for their sickness. The proportion for patients doesn't have access to proper treatment from a CM specialist or oncology, and would instead rely on the Web or word-of-mouth for data. Even though it's been formed that using "alternate solution" treatments for treatable types of cancer not related to conventional antitumor agents may start increasing mortality rates, this trend of ego & refusal of conventional treatments has been permanent instead of having to pass in Italy. People with cancer who used CMs had greater rejection percentages for operation, RT, CT, & ET, according to a new analysis. Participants who used CM had a lower 5-year total rate of survival than those who didn't, and it was linked to a greater risk of dying.

Moreover, complex interplay seems to perform a beneficial function in reducing RT-induced skin damage, which has been established in the research.10,24, when contrasted to compared to the untreated cohort, a simple therapy regimen centered on the oral or topical application of homeopathic medicines & herb salve during treatment toward CT appears to be effective by preventing the amount of destruction to the skin in the majority of the patients. More randomized controlled trials, which would use particular economical techniques of assessment, were needed to corroborate these findings, at least for the most commonly occurring symptoms. These first findings also are promising, especially when considering that this strategy is cost-effective, long-term, & relatively straightforward to implement.

## CONCLUSIONS

Integrating scientific proof supplementary treatment options considered to be an effective reaction to people with cancer' demands for a reduction in the side effects for antitumor agents & also melanoma symptomatology to improve patient safety & quality of life and equity for access within the public healthcare systems. Physicians & other healthcare workers in the field, therefore be properly informed of positive implications for CM.

## ACKNOWLEDGEMENT

The authors acknowledge the subjects who were involved in the study.

## CONFLICT OF INTEREST

The authors declare that there is no conflict of interest for this study

## REFERENCES

1. Forbes, N. S., Coffin, R. S., Deng, L., Evgeni, L., Fiering, S., Giacalone, M., ... & McFadden, G. (2018). White paper on microbial anti-cancer therapy and prevention. *Journal for immunotherapy of cancer*, 6(1), 1-24.
2. Ezhilarasi, T. P., Sudheer Kumar, N., Latchoumi, T. P., & Balayesu, N. (2021). A secure data sharing using IDSS CP-ABE in cloud storage. In *Advances in Industrial Automation and Smart Manufacturing* (pp. 1073-1085). Springer, Singapore.
3. Latchoumi, T. P., & Parthiban, L. (2021). Quasi oppositional dragonfly algorithm for load balancing in cloud computing environment. *Wireless Personal Communications*, 1-18.
4. Latchoumi, T. P., Swathi, R., Vidyasri, P., & Balamurugan, K. (2022, March). Develop New Algorithm To Improve Safety On WMSN In Health Disease Monitoring. In *2022 International Mobile and Embedded Technology Conference (MECON)* (pp. 357-362). IEEE.
5. Pavan, V. M., Balamurugan, K., & Latchoumi, T. P. (2021). PLA-Cu reinforced composite filament: Preparation and flexural property printed at different machining conditions. *Advanced composite materials*.
6. Latchoumi, T. P., Balamurugan, K., Dinesh, K., & Ezhilarasi, T. P. (2019). Particle swarm optimization approach for waterjet cavitation peening. *Measurement*, 141, 184-189.
7. Latchoumi, T. P., Kalusuraman, G., Banu, J. F., Yookesh, T. L., Ezhilarasi, T. P., & Balamurugan, K. (2021, November). Enhancement in manufacturing systems using Grey-Fuzzy and LK-SVM approach. In *2021 IEEE International Conference on Intelligent Systems, Smart and Green Technologies (ICISSGT)* (pp. 72-78). IEEE.
8. Wang, Z., Qi, F., Cui, Y., Zhao, L., Sun, X., Tang, W., & Cai, P. (2018). An update on Chinese herbal medicines as adjuvant treatment of anticancer therapeutics. *Bioscience Trends*, 12(3), 220-239.
9. Karnan, B., Kuppusamy, A., Latchoumi, T. P., Banerjee, A., Sinha, A., Biswas, A., & Subramanian, A. K. (2022). Multi-response Optimization of Turning Parameters for Cryogenically Treated and Tempered WC-Co Inserts. *Journal of The Institution of Engineers (India): Series D*, 1-12.

10. Jaswal, V., Palanivelu, J., & Ramalingam, C. (2018). Effects of the Gut microbiota on amygdalin and its use as an anti-cancer therapy: substantial review on the key components involved in altering dose efficacy and toxicity. *Biochemistry and biophysics reports*, 14, 125-132.
11. Villa, F., Quarto, R., & Tasso, R. (2019). Extracellular vesicles as natural, safe, and efficient drug delivery systems. *Pharmaceutics*, 11(11), 557.
12. Tomeh, M. A., Hadianamrei, R., & Zhao, X. (2019). A review of curcumin and its derivatives as anticancer agents. *International journal of molecular sciences*, 20(5), 1033.
13. Tong, X., Pan, W., Su, T., Zhang, M., Dong, W., & Qi, X. (2020). Recent advances in natural polymer-based drug delivery systems. *Reactive and Functional Polymers*, 148, 104501.
14. Deepthi, T., Balamurugan, K., & Uthayakumar, M. (2021). Simulation and experimental analysis on cast metal run behavior rate at different gating models. *International Journal of Engineering Systems Modelling and Simulation*, 12(2-3), 156-164.
15. Khan, T., & Gurav, P. (2018). PhytoNanotechnology: Enhancing the delivery of plant-based anti-cancer drugs. *Frontiers in pharmacology*, 8, 1002.
16. Tewari, D., Rawat, P., & Singh, P. K. (2019). Adverse drug reactions of anticancer drugs derived from natural sources. *Food and Chemical Toxicology*, 123, 522-535.
17. Arunkarthikeyan, K., & Balamurugan, K. (2021). Studies on the impact of soaking time on a cryogenic processed and post tempered WC-Co insert. *Materials Today: Proceedings*, 44, 1692-1699.
18. Parveen, A., Subedi, L., Kim, H. W., Khan, Z., Zahra, Z., Farooqi, M. Q., & Kim, S. Y. (2019). Phytochemicals targeting VEGF and VEGF-related multi factors as anticancer therapy. *Journal of clinical medicine*, 8(3), 350.
19. Latchoumi, T. P., Ezhilarasi, T. P., & Balamurugan, K. (2019). Bio-inspired weighed quantum particle swarm optimization and smooth support vector machine ensembles for identification of abnormalities in medical data. *SN Applied Sciences*, 1(10), 1-10.

#### CITATION OF THIS ARTICLE

S.Mariselvi, Alok Tiwari, Sivakumar Ponnusamy, E.N. Gaviraj, Alternative medicines to enhance the efficacy and safety of Anticancer therapy., *Bull. Env. Pharmacol. Life Sci.*, Vol 11[6] May 2022: 12-16